TSHR; NMUR2; | |
ADRA2C; ADRA2A; GPER1; | |
ALPI; RECQL; TDP1; BLM; AKR1B1; HSD17B2; ALDH1A1; HSD17B1; AOX1; POLB; | |
ACHE; GAA; MGAM; | |
ABL1; MAPK1; EGFR; | |
CA2; CA12; CA7; CA4; | |
AR; | |
ESR1; ESR2; | |
ESRRB; ESRRA; | |
MAOA; | |
HIF1A; TP53; | |
SLC22A3; SLC22A1; SLCO1B3; SLCO1B1; | |
ABCG2; | |
RAB9A; NPC1; SERPINA6; LMNA; SHBG; THPO; | |
SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2B6 | Cytochrome P450 2B6 | P20813 | CHEMBL4729 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
SLC superfamily of solute carriers | SLC22A3 | Solute carrier family 22 member 3 | O75751 | CHEMBL2073673 |
SLC superfamily of solute carriers | SLC22A1 | Solute carrier family 22 member 1 | O15245 | CHEMBL5685 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Small molecule receptor (family A GPCR) | GPER1 | G-protein coupled estrogen receptor 1 | Q99527 | CHEMBL5872 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | SERPINA6 | Corticosteroid binding globulin | P08185 | CHEMBL2421 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | SHBG | Testis-specific androgen-binding protein | P04278 | CHEMBL3305 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 9.061E-11 | 3.288E-07 | CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.975E-10 | 2.170E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 3.331E-08 | 4.267E-05 | ADRA2A, CA2, CA4, EGFR, SLC22A1, SLCO1B1, SLCO1B3, TSHR |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.235E-08 | 7.146E-05 | CA12, CA2, CA4, CA7 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 7.347E-08 | 7.272E-05 | CYP1A2, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0005497; androgen binding | 7.347E-08 | 7.272E-05 | ALDH1A1, AR, SHBG |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.307E-07 | 1.139E-04 | CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP3A4 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.499E-07 | 1.256E-04 | ABL1, CA2, CA7, EGFR, GPER1, HIF1A, MAPK1, NPC1 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.295E-07 | 1.612E-04 | AOX1, CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP3A4, TBXAS1 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.701E-07 | 1.782E-04 | CYP1A2, CYP2B6, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 4.387E-07 | 2.388E-04 | AKR1B1, ALDH1A1, CYP3A4, ESR1, HSD17B1, HSD17B2 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.194E-06 | 5.651E-04 | CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP3A4, TBXAS1 |
BP | GO:0051179; localization | GO:0015850; organic hydroxy compound transport | 1.249E-06 | 5.668E-04 | ABCG2, NPC1, SLC22A1, SLC22A3, SLCO1B1, SLCO1B3 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.245E-06 | 5.668E-04 | ALPI, AR, BLM, CA12, CA2, CA4, CA7, ESR1, ESR2, ESRRA, ESRRB, TP53 |
BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 1.528E-06 | 6.333E-04 | BLM, RECQL, TP53 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 2.040E-06 | 7.931E-04 | CYP2B6, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.179E-06 | 8.324E-04 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.581E-06 | 9.365E-04 | CA12, CA2, CA4, CA7 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.980E-06 | 1.313E-03 | CYP1A2, CYP2C9, CYP3A4 |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 4.385E-06 | 1.404E-03 | ABL1, ADRA2A, CA2, CA7, EGFR, GPER1, HIF1A, MAPK1, NPC1 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.853E-06 | 1.770E-03 | CA12, CA2, CA4, CA7 |
BP | GO:0065007; biological regulation | GO:0043006; activation of phospholipase A2 activity by calcium-mediated signaling | 7.108E-06 | 2.010E-03 | EGFR, NMUR2 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 7.108E-06 | 2.010E-03 | ESR1, ESR2 |
BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 9.761E-06 | 2.561E-03 | ABL1, AKR1B1, BLM, EGFR, GPER1, MAPK1, TP53, TSHR |
BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.050E-05 | 2.721E-03 | ABL1, AKR1B1, EGFR, MAPK1, TP53 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 1.218E-05 | 3.015E-03 | CYP2B6, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.366E-05 | 3.304E-03 | CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.641E-05 | 3.683E-03 | ABCG2, ACHE, ADRA2A, ADRA2C, AOX1, BLM, EGFR, ESR1, ESR2, MAPK1, RAB9A, SLC22A1, SMN1, SMN2, TP53 |
BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 1.928E-05 | 4.157E-03 | ABL1, ADRA2A, AKR1B1, AR, EGFR, ESR1, GPER1, HIF1A, MAPK1, THPO, TSHR |
BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 2.031E-05 | 4.292E-03 | EGFR, ESRRB, HIF1A |
BP | GO:0008152; metabolic process | GO:0000023; maltose metabolic process | 2.129E-05 | 4.292E-03 | GAA, MGAM |
BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 2.129E-05 | 4.292E-03 | ABL1, HIF1A |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.129E-05 | 4.292E-03 | CA2, CA7 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 2.129E-05 | 4.292E-03 | ADRA2A, ADRA2C |
MF | GO:0003824; catalytic activity | GO:0032450; maltose alpha-glucosidase activity | 2.129E-05 | 4.292E-03 | GAA, MGAM |
BP | GO:0009987; cellular process | GO:0007189; adenylate cyclase-activating G-protein coupled receptor signaling pathway | 4.196E-05 | 7.464E-03 | ADRA2A, ADRA2C, GPER1, TSHR |
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 4.250E-05 | 7.464E-03 | ADRA2A, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 4.250E-05 | 7.464E-03 | ADRA2A, ADRA2C |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 4.250E-05 | 7.464E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0004558; alpha-1,4-glucosidase activity | 4.250E-05 | 7.464E-03 | GAA, MGAM |
MF | GO:0003824; catalytic activity | GO:0016712; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | 4.580E-05 | 7.978E-03 | CYP1A2, CYP2B6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0042327; positive regulation of phosphorylation | 5.382E-05 | 9.103E-03 | ABL1, ADRA2A, ADRA2C, AR, EGFR, ESRRB, GPER1, HIF1A, MAPK1, THPO, TP53 |
BP | GO:0009987; cellular process | GO:0030518; intracellular steroid hormone receptor signaling pathway | 5.749E-05 | 9.629E-03 | AR, ESR1, ESR2, GPER1 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 3.659E-16 | 7.967E-12 | AR, CYP3A4, ESR1, ESR2, ESRRA, ESRRB, GPER1, HSD17B1, NPC1, SERPINA6, SHBG |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 5.035E-10 | 7.955E-08 | CYP2C9; CYP2B6; MAOA; CYP1A2; AOX1; CYP3A4; CYP2C19 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.685E-08 | 1.331E-06 | CYP2C9; CYP2B6; CYP1A2; ALDH1A1; AOX1; CYP3A4 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.887E-08 | 1.521E-06 | SLCO1B1; CA2; SLCO1B3; SLC22A1; CYP3A4; ABCG2 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.555E-07 | 1.124E-05 | MGAM; MAOA; GAA; AKR1B1; CYP2C19; CYP3A4; CYP2C9; CYP2B6; HSD17B1; TBXAS1; HSD17B2; CYP1A2; ALDH1A1; AOX1; ALPI |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 5.801E-06 | 1.264E-04 | GPER1; MAPK1; ESR1; EGFR; ESR2 |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 6.399E-06 | 1.264E-04 | SLC22A3; SLC22A1; MAPK1; HIF1A; EGFR |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 9.195E-07 | 2.421E-05 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 9.429E-08 | 3.725E-06 | CA12; CA2; CA4; CA7 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.027E-05 | 3.203E-04 | CYP2C9; CYP2B6; TBXAS1; CYP2C19 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.759E-05 | 3.963E-04 | MAPK1; TP53; HIF1A; EGFR |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.554E-05 | 2.728E-04 | HSD17B1; CYP1A2; HSD17B2; CYP3A4 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.873E-05 | 5.099E-04 | CYP2C9; CYP2B6; CYP1A2; CYP3A4 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 8.425E-05 | 8.875E-04 | AR; MAPK1; TP53; EGFR |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.809E-04 | 1.588E-03 | MAPK1; TP53; HIF1A; ESR1; EGFR |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 6.117E-05 | 7.228E-04 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.051E-04 | 1.705E-03 | CYP2C9; MAOA; MAPK1; CYP2C19 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 5.546E-04 | 3.810E-03 | AR; ABL1; MAPK1; HIF1A; TP53; EGFR |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.505E-04 | 1.979E-03 | MAPK1; TP53; ESR1; HIF1A |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.530E-04 | 1.511E-03 | MAOA; CYP1A2; AOX1 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.648E-04 | 1.532E-03 | MAPK1; TP53; EGFR |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 4.169E-04 | 2.994E-03 | MAPK1; TP53; EGFR |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 3.348E-04 | 2.519E-03 | MAPK1; TP53; EGFR |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 6.462E-04 | 4.254E-03 | MAPK1; TP53; EGFR |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 6.405E-05 | 7.228E-04 | MGAM; GAA; AKR1B1 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 6.758E-04 | 4.271E-03 | MAPK1; TP53; EGFR |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 8.364E-04 | 5.083E-03 | MAPK1; TP53; EGFR |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 8.711E-04 | 5.098E-03 | MAPK1; ESR1; ESR2 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 9.068E-04 | 5.117E-03 | ABL1; MAPK1; TP53 |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.506E-03 | 8.207E-03 | ABL1; MAPK1; EGFR |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.441E-03 | 1.205E-02 | MAPK1; HIF1A; EGFR |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 3.758E-03 | 1.697E-02 | ABL1; MAPK1; TP53 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 5.775E-03 | 2.406E-02 | LMNA; MAPK1; TP53 |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 5.787E-03 | 2.406E-02 | NMUR2; ADRA2C; ADRA2A; TSHR |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 5.009E-03 | 2.199E-02 | MAPK1; TP53; EGFR |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 7.374E-03 | 2.962E-02 | ABL1; MAPK1; TP53; EGFR |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 9.367E-03 | 3.524E-02 | MAPK1; ADRA2C; ADRA2A |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.066E-02 | 3.916E-02 | MAPK1; HIF1A |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.135E-02 | 4.076E-02 | MAPK1; TP53 |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.279E-02 | 4.348E-02 | MAPK1; HIF1A |
hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 9.335E-03 | 3.524E-02 | MGAM; GAA |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 7.500E-03 | 2.962E-02 | HSD17B1; HSD17B2 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.242E-02 | 4.348E-02 | ABL1; MAPK1 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 2.574E-03 | 1.232E-02 | MAPK1; TP53 |
hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 3.734E-03 | 1.697E-02 | MAOA; AOX1 |
hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 2.232E-03 | 1.138E-02 | MAPK1; EGFR |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.620E-03 | 8.531E-03 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.293E-02 | 4.348E-02 | CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE; ADRA2C; MAOA |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; MAOA |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; ACHE; ESR1; ADRA2C; ADRA2A |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | SERPINA6 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; ESRRA |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
C00-D49: Neoplasms | Myeloid leukemia | C92 | ABL1 |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; ABL1; EGFR; ESR1 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1 |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; ADRA2C |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TBXAS1 |
A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
NA: NA | Upper abdominal bloating | NA | ACHE |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; EGFR |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; EGFR |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
C00-D49: Neoplasms | Breast cancer | C50 | AR; EGFR; EGFR; EGFR; ESR1; ESR1 |
C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; ESR1 |
NA: NA | Edema | NA | CA2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C; MAOA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; ACHE; HIF1A; TP53; ABL1; MAPK1; EGFR; ESR1; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; ABL1; MAPK1; EGFR |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; MGAM |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1 |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; EGFR; EGFR; EGFR; AKR1B1 |
A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESR1; ESRRA |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
NA: NA | Postmenopausal disorder | NA | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA; MGAM |
C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; EGFR |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
J00-J99: Diseases of the respiratory system | Asthma | J45 | TBXAS1; ADRA2C; SERPINA6; ESRRA |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; EGFR; EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; ESRRA |
C00-D49: Neoplasms | Leukemia | C90-C95 | ABL1; ESR1 |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; ADRA2C |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; MGAM |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; MAOA |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | ABL1 |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
NA: NA | Menopausal disorder | NA | ESR1 |
C00-D49: Neoplasms | Melanoma | C43 | EGFR |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | ABL1 |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
C00-D49: Neoplasms | Glioma | C71 | ABL1; EGFR; EGFR |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | SERPINA6 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic macular edema | E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9 | SERPINA6 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
NA: NA | Male hypogonadism | NA | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | TBXAS1; MGAM |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
NA: NA | Obstructive airway diseases | NA | SERPINA6 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; EGFR |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; CYP3A4; MAOA |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; ESRRA |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |